近期放射治疗随机临床试验中改变实践的数据与新兴概念
该综述通过检索Medline数据库2018至2021年发表的放射治疗随机对照试验,梳理了改变临床实践的最新证据与新兴概念,涵盖放射免疫治疗、新型促凋亡药物、纳米颗粒、立体定向体部放疗、基于影像或生物标志物的个体化放疗以及(超)大分割方案等方向。
要点
- 放射免疫治疗、促凋亡药物和纳米颗粒等联合策略在早期或转移性肺癌、局部晚期头颈鳞癌和局部晚期软组织肉瘤中获得随机证据支持。
- 基于18FDG PET-CT、PSMA PET-CT或MRI以及PSA、HPV等生物标志物的个体化放疗已开展首批随机研究,并获得更有利的结局。
- 多项随机对照试验验证了乳腺、前列腺和直肠癌等适应证的(超)大分割方案,结局和毒性等效且更方便患者。
核心结论
- 放射治疗是一个活跃的研究领域,过去数年间多项随机对照试验对治疗标准产生了重大影响。
- 作者认为,对放射治疗研究的投入应促进创新向临床转化。
研究设计与样本
- 本文为综述,检索Medline数据库以识别2018年至2021年发表的所有报告放射治疗随机对照试验的文献。
主要发现
- 近期随机对照试验通过放射免疫治疗支持了早期或转移性肺癌的新联合策略。
- 新型促凋亡药物(如Debio 1143用于局部晚期头颈鳞状细胞癌)或纳米颗粒(如NBTXR3用于局部晚期软组织肉瘤)获得随机试验支持。
- 立体定向体部放疗等高科技放疗使治疗强度得以提升并在部分适应证中取得进展。
- 基于18FDG PET-CT(肺癌或早期不良型霍奇金淋巴瘤)、PSMA PET-CT或MRI(高危前列腺癌)以及PSA(前列腺癌)、HPV(头颈癌)等生物标志物的个体化放疗首批随机证据已开展,并获得更有利的结局。
- 随机对照试验在乳腺、前列腺或直肠癌等多个适应证中验证了(超)大分割方案,结局和毒性等效,对患者更方便并有利于共享决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Oncology treatments are constantly and rapidly evolving. We aimed at highlighting the latest radiation therapy practice changing trials and emerging concepts, through an overview of recent randomised clinical trials (RCTs). MATERIALS AND METHODS: Requests were performed in the Medline database to identify all publications reporting radiation therapy RCTs from 2018 to 2021. RESULTS: Recent RCTs sustained the role of newer combinatorial strategies through radioimmunotherapy for early stage or metastatic lung cancer, newer pro-apoptotic agents (e.g. debio 1143 in locoregionally advanced head and neck squamous cell carcinoma) or nanoparticles (e.g. NBTXR3 in locally advanced soft-tissue sarcoma). High-tech radiotherapy allows intensifying treatments and gaining ground in some indications through the development of stereotactic body radiotherapy for example. First randomised evidence on personalised radiation therapy through imaging-based (18FDG positron emission tomography-computed tomography for lung cancer or early stage unfavourable Hodgkin lymphoma, PMSA positron emission tomography-computed tomography or magnetic resonance imaging for high-risk prostate cancer) or biological biomarkers (PSA for prostate cancer, HPV for head and neck cancer, etc) were conducted to more tailored treatments, with more favourable outcomes. Patients' quality of life and satisfaction appeared to be increasing aims. RCTs have validated (ultra)hypofractionated schemes in many indications as for breast, prostate or rectal cancer, resulting in equivalent outcomes and toxicities, more convenient for patients and favouring shared decision making. CONCLUSION: Radiation therapy is a dynamic field of research, and many RCTs have greatly impacted therapeutic standards over the last years. Investments in radiotherapy research should facilitate the transfer of innovation to clinic.
引用
- Espenel S, Chargari C, Blanchard P, et al. Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials. Eur J Cancer. 2022. PMID: 35779346. doi:10.1016/j.ejca.2022.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。